Vestal Point Capital, L.P. 13F annual report
Vestal Point Capital, L.P. is an investment fund managing more than $1.34 trillion ran by Ilko Menkov. There are currently 60 companies in Mr. Menkov’s portfolio. The largest investments include Jazz Pharmaceuticals plc and Cytokinetics Inc, together worth $273 billion.
$1.34 trillion Assets Under Management (AUM)
As of 7th August 2024, Vestal Point Capital, L.P.’s top holding is 1,500,000 shares of Jazz Pharmaceuticals plc currently worth over $160 billion and making up 11.9% of the portfolio value.
Relative to the number of outstanding shares of Jazz Pharmaceuticals plc, Vestal Point Capital, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 2,075,000 shares of Cytokinetics Inc worth $112 billion, whose value fell 26.7% in the past six months.
The third-largest holding is Ascendis Pharma A/S worth $102 billion and the next is Ultragenyx Pharmaceutical worth $74 billion, with 1,800,000 shares owned.
Currently, Vestal Point Capital, L.P.'s portfolio is worth at least $1.34 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Vestal Point Capital, L.P.
The Vestal Point Capital, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Ilko Menkov serves as the Partner, COO and CCO at Vestal Point Capital, L.P..
Recent trades
In the most recent 13F filing, Vestal Point Capital, L.P. revealed that it had opened a new position in
Janux Therapeutics Inc and bought 725,000 shares worth $30.4 billion.
The investment fund also strengthened its position in Jazz Pharmaceuticals plc by buying
400,000 additional shares.
This makes their stake in Jazz Pharmaceuticals plc total 1,500,000 shares worth $160 billion.
Jazz Pharmaceuticals plc dropped 20.2% in the past year.
On the other hand, there are companies that Vestal Point Capital, L.P. is getting rid of from its portfolio.
Vestal Point Capital, L.P. closed its position in Neurocrine Biosciences on 14th August 2024.
It sold the previously owned 710,000 shares for $97.9 billion.
Ilko Menkov also disclosed a decreased stake in Cytokinetics Inc by approximately 0.1%.
This leaves the value of the investment at $112 billion and 2,075,000 shares.
One of the largest hedge funds
The two most similar investment funds to Vestal Point Capital, L.P. are Natixis Investment Managers International and Chai Trust Co. They manage $1.34 trillion and $1.34 trillion respectively.
Ilko Menkov investment strategy
Vestal Point Capital, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 84.1% of
the total portfolio value.
The fund focuses on investments in the United States as
63.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only 5.0% of the portfolio.
The average market cap of the portfolio companies is close to $7.41 billion.
The complete list of Vestal Point Capital, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Jazz Pharmaceuticals plc |
36.36%
1,500,000
|
$160,095,000,000 | 11.94% |
| Cytokinetics Inc |
3.49%
2,075,000
|
$112,423,500,000 | 8.38% |
| Ascendis Pharma A/S |
42.86%
750,000
|
$102,285,000,000 | 7.63% |
| Neurocrine Biosciences, Inc. |
Closed
710,000
|
$97,923,200,000 | |
| Ultragenyx Pharmaceutical Inc. |
1,536.36%
1,800,000
|
$73,980,000,000 | 5.52% |
| Globus Medical Inc |
10.00%
900,000
|
$61,641,000,000 | 4.60% |
| Alnylam Pharmaceuticals Inc |
Closed
350,000
|
$52,307,500,000 | |
| Insmed Inc |
No change
750,000
|
$50,250,000,000 | 3.75% |
| BeiGene Ltd |
7.69%
350,000
|
$49,934,500,000 | 3.72% |
| Soleno Therapeutics Inc |
4.00%
1,200,000
|
$48,960,000,000 | 3.65% |
| Exact Sciences Corp. |
825.00%
925,000
|
$39,081,250,000 | 2.91% |
| Arcellx Inc |
575.00%
675,000
|
$37,253,250,000 | 2.78% |
| Immatics Nv |
129.17%
2,750,000
|
$31,955,000,000 | 2.38% |
| Janux Therapeutics Inc |
Opened
725,000
|
$30,370,250,000 | 2.26% |
| Astria Therapeutics Inc |
195.45%
3,250,000
|
$29,575,000,000 | 2.21% |
| Astrazeneca plc |
Closed
400,000
|
$27,100,000,000 | |
| KalVista Pharmaceuticals Inc |
251.15%
2,300,000
|
$27,094,000,000 | 2.02% |
| Savara Inc |
Opened
6,490,000
|
$26,154,700,000 | 1.95% |
| iTeos Therapeutics, Inc. |
Opened
1,750,000
|
$25,970,000,000 | 1.94% |
| Applied Therapeutics, Inc. |
6.26%
5,430,000
|
$25,358,100,000 | 1.89% |
| Axsome Therapeutics Inc |
Opened
300,000
|
$24,150,000,000 | 1.80% |
| Structure Therapeutics Inc |
Opened
560,000
|
$21,991,200,000 | 1.64% |
| Liquidia Corp |
8.50%
1,830,000
|
$21,960,000,000 | 1.64% |
| ALX Oncology Holdings Inc. |
37.93%
3,600,000
|
$21,708,000,000 | 1.62% |
| Uniqure Nv |
0.53%
4,750,000
|
$21,280,000,000 | 1.59% |
| Bristol-Myers Squibb Co. |
Opened
500,000
|
$20,765,000,000 | 1.55% |
| Xenon Pharmaceuticals Inc |
31.25%
525,000
|
$20,469,750,000 | 1.53% |
| Argenx Se |
Closed
50,000
|
$19,686,000,000 | |
| Praxis Precision Medicines, Inc. |
109.52%
440,000
|
$18,198,400,000 | 1.36% |
| Day One Biopharmaceuticals Inc |
Opened
1,250,000
|
$17,225,000,000 | 1.28% |
| Inari Medical, Inc. |
56.25%
350,000
|
$16,852,500,000 | 1.26% |
| TG Therapeutics Inc |
Closed
1,050,000
|
$15,970,500,000 | |
| Dianthus Therapeutics Inc |
31.87%
600,000
|
$15,528,000,000 | 1.16% |
| Biomarin Pharmaceutical Inc. |
Closed
175,000
|
$15,284,500,000 | |
| Solid Biosciences Inc |
157.49%
2,665,000
|
$15,110,550,000 | 1.13% |
| Alpine Immune Sciences Inc |
Closed
350,000
|
$13,874,000,000 | |
| Lexeo Therapeutics Inc |
380.00%
840,000
|
$13,473,600,000 | 1.00% |
| Sarepta Therapeutics Inc |
Closed
100,000
|
$12,946,000,000 | |
| Apellis Pharmaceuticals Inc |
48.89%
335,000
|
$12,850,600,000 | 0.96% |
| Immunome, Inc. |
Opened
1,000,000
|
$12,100,000,000 | 0.90% |
| Denali Therapeutics Inc |
Opened
500,000
|
$11,610,000,000 | 0.87% |
| Incyte Corp. |
Closed
200,000
|
$11,394,000,000 | |
| Nurix Therapeutics, Inc. |
Opened
500,000
|
$10,435,000,000 | 0.78% |
| Black Diamond Therapeutics Inc |
Opened
2,100,000
|
$9,786,000,000 | 0.73% |
| Agios Pharmaceuticals Inc |
Closed
325,000
|
$9,503,000,000 | |
| Shockwave Medical Inc. |
Closed
25,000
|
$8,140,750,000 | |
| BioNTech SE |
Opened
100,000
|
$8,036,000,000 | 0.60% |
| Inspire Medical Systems Inc |
Opened
60,000
|
$8,029,800,000 | 0.60% |
| Pacira BioSciences Inc |
250.00%
280,000
|
$8,010,800,000 | 0.60% |
| Krystal Biotech Inc |
Closed
45,000
|
$8,006,850,000 | |
| Dyne Therapeutics, Inc. |
Opened
225,000
|
$7,940,250,000 | 0.59% |
| Geron Corp. |
Closed
2,200,000
|
$7,260,000,000 | |
| Fulcrum Therapeutics Inc |
66.91%
1,160,000
|
$7,192,000,000 | 0.54% |
| Alto Neuroscience Inc |
148.00%
620,000
|
$6,627,800,000 | 0.49% |
| Fate Therapeutics Inc |
150.00%
2,000,000
|
$6,560,000,000 | 0.49% |
| Viking Therapeutics Inc |
Closed
75,000
|
$6,150,000,000 | |
| Bio-Rad Laboratories Inc. |
Closed
15,000
|
$5,188,050,000 | |
| Allogene Therapeutics Inc |
62.96%
2,200,000
|
$5,126,000,000 | 0.38% |
| Lyra Therapeutics, Inc. |
Closed
800,000
|
$4,976,000,000 | |
| Passage Bio Inc |
34.49%
6,052,000
|
$4,806,498,000 | 0.36% |
| Voyager Therapeutics Inc |
No change
600,000
|
$4,746,000,000 | 0.35% |
| Galapagos NV |
38.46%
180,000
|
$4,460,400,000 | 0.33% |
| Zymeworks Inc |
Opened
440,000
|
$3,744,400,000 | 0.28% |
| Relmada Therapeutics Inc |
No change
1,200,000
|
$3,600,000,000 | 0.27% |
| Macrogenics Inc |
10.34%
800,000
|
$3,400,000,000 | 0.25% |
| Monte Rosa Therapeutics Inc |
Opened
890,000
|
$3,328,600,000 | 0.25% |
| Ventyx Biosciences Inc |
Opened
1,315,000
|
$3,037,650,000 | 0.23% |
| PTC Therapeutics Inc |
Opened
90,000
|
$2,752,200,000 | 0.21% |
| Verve Therapeutics Inc |
Opened
500,000
|
$2,440,000,000 | 0.18% |
| Iovance Biotherapeutics Inc |
Opened
300,000
|
$2,406,000,000 | 0.18% |
| Novavax, Inc. |
Closed
500,000
|
$2,390,000,000 | |
| Prime Medicine Inc |
25.00%
450,000
|
$2,313,000,000 | 0.17% |
| Atara Biotherapeutics Inc |
Closed
2,800,000
|
$1,943,200,000 | |
| Chimerix Inc |
No change
1,400,000
|
$1,226,400,000 | 0.09% |
| Achilles Therapeutics Plc |
No change
1,500,000
|
$1,222,500,000 | 0.09% |
| Atara Biotherapeutics Inc |
Opened
112,000
|
$952,000,000 | 0.07% |
| Reneo Pharmaceuticals Inc |
84.51%
545,000
|
$822,950,000 | 0.06% |
| Newamsterdam Pharma Co Nv |
Opened
25,000
|
$480,250,000 | 0.04% |
| Affimed Nv |
Closed
55,000
|
$291,500,000 | |
| Lyell Immunopharma Inc |
Closed
130,000
|
$289,900,000 | |
| No transactions found | |||
| Showing first 500 out of 80 holdings | |||
Hedge funds similar to Vestal Point Capital, L.P.
- Guyasuta Investment Advisors Inc
- Howard Capital Management
- Krilogy
- Fulton Breakefield Broenniman
- Procyon Advisors
- Quadrant Capital Group
- First Trust Direct Indexing L.P.
- Natixis Investment Managers International
- Chai Trust Co
- Mirae Asset Securities (usa) Inc
- Atomi
- Steel Peak Wealth Management
- Ctc
- Jana Partners